Navigation Links
InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
Date:9/30/2009

LOS ALTOS, Calif., Sept. 30 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today positive results for INT131 in a 24 week Phase 2b study at the 45th European Association for the Study of Diabetes Meeting in Vienna, Austria. An overview of the data will be presented at 1:45 PM Friday, October 2, 2009 by InteKrin Therapeutics' Chief Medical Officer, Alex DePaoli, MD. His presentation is entitled "Impact of INT131 Besylate, a Selective PPAR-gamma Modulator (SPPARM), on Glycemic Control in Patients with Type 2 Diabetes in a 24-Week Phase 2b Study (INT131-007)." In this study INT131 demonstrated a superior side effect profile with comparable efficacy when tested side-by-side against 45 mgs daily pioglitazone (Actos®).

"INT131 provided potent glucose lowering with minimal body weight gain, hematocrit reduction, or evidence of edema at 1 mg, replicating the results of the earlier 4-week Phase 2a study," said Dr. DePaoli. "These data validate the activity of INT131 as a potent selective PPAR-gamma modulator (SPPARM) with significant glucose lowering properties and without the edema or degree of body weight gain seen with pioglitazone." There was no difference in incidence or severity of edema in any INT131 dose group compared to placebo, while the expected increase in frequency and severity of edema was observed in the pioglitazone group.

"These data confirm INT131 to be an advance for patients who suffer with this disease," noted Denny Lanfear, InteKrin President and Chief Executive Officer. "As diabetes has become an epidemic throughout the world, physicians desperately need a safe insulin sensitizer in their diabetes therapeutic armamentarium that does not have the safety and tolerability shortcomings of the existing therapies."

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. INT131 has been designed to provide a safer therapeutic tool for physicians and patients, which is complementary to available classes of medications, and allows for powerful glucose control and the opportunity for modification of the underlying disease. As a SPPARM, INT131 selectively modulates PPAR-gamma, and is ideally positioned to safely improve insulin resistance, addressing an important unmet medical need.

About InteKrin (www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

SOURCE InteKrin Therapeutics Inc.


'/>"/>
SOURCE InteKrin Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
2. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
3. Reportlinker Adds Stem Cell Therapeutics Markets Report
4. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
5. Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index
6. Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference
7. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
8. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
9. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
10. Orexigen(R) Therapeutics to Speak at UBS Global Life Sciences Conference
11. Pervasis Therapeutics Announces $17 Million in Financing and New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/10/2017)... PITTSBURGH, PA (PRWEB) , ... October 10, 2017 ... ... this year’s recipients of 13 prestigious awards honoring scientists who ... be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference ...
Breaking Biology Technology:
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
Breaking Biology News(10 mins):